NCT07815249 Speech Therapy for Children With Rare Genetic Conditions and Childhood Apraxia of Speech
| NCT ID | NCT07815249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Murdoch Childrens Research Institute |
| Condition | Childhood Apraxia of Speech |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-07-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this trial is to learn if speech therapy can improve speech accuracy in children with rare genetic conditions and childhood apraxia of speech (CAS). This study will look at each child individually. Participants will complete 4-weeks of motor speech therapy (3 times per week) and will complete speech assessments before, during and after therapy to measure change. The motor speech therapy will be either Rapid Syllable Transition Treatment (ReST) or Dynamic Temporal and Tactile Cueing (DTTC). Assignment to ReST or DTTC will be based on the participant's age and speech ability. This trial will not compare ReST and DTTC.
Eligibility Criteria
Inclusion Criteria: * Children aged between 3 and 16 years, with a confirmed genetic condition and a diagnosis of childhood apraxia of speech; English as the primary language at home; able to participate in speech therapy 3 times per week for 4 weeks Exclusion Criteria: * Diagnosis of an acquired brain or movement condition likely to affect speech; currently receiving motor speech therapy in the community; diagnosis of a behavioural condition likely to impact engagement (i.e., unable to participate for 45 minutes, unable to focus attention at the speech therapist's face for a few minutes at a time, unable to say any sounds and/or use gesture, unable to try to copy speech therapist; intolerant to touch (if touch cues are needed for DTTC)
Contact & Investigator
Miya D St John, PhD
PRINCIPAL INVESTIGATOR
Murdoch Childrens Research Institute
Frequently Asked Questions
Who can join the NCT07815249 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 16 Years, studying Childhood Apraxia of Speech. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07815249 currently recruiting?
Yes, NCT07815249 is actively recruiting participants. Contact the research team at miya.stjohn@mcri.edu.au for enrollment information.
Where is the NCT07815249 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT07815249 clinical trial?
NCT07815249 is sponsored by Murdoch Childrens Research Institute. The principal investigator is Miya D St John, PhD at Murdoch Childrens Research Institute. The trial plans to enroll 20 participants.